Scott Rowlinson - Aeglea Bio Vice President - Research
| AGLEDelisted Stock | USD 0.59 0.01 1.72% |
President
Dr. Scott W. Rowlinson, Ph.D. is Vice President Research of the Company. From May 2000 to February 2014, Dr. Rowlinson worked as a research scientist at Eli Lilly Company, a pharmaceutical company since 2014.
| Age | 54 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Phone | 512 942 2935 |
| Web | https://www.aeglea.com |
Aeglea Bio Management Efficiency
The company has return on total asset (ROA) of (0.4182) % which means that it has lost $0.4182 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.8141) %, meaning that it created substantial loss on money invested by shareholders. Aeglea Bio's management efficiency ratios could be used to measure how well Aeglea Bio manages its routine affairs as well as how well it operates its assets and liabilities.Aeglea Bio Therapeutics currently holds 4.63 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Aeglea Bio Therapeutics has a current ratio of 4.56, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Aeglea Bio's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 6 records | PRESIDENT Age | ||
| Kanya MD | Senti Biosciences | 50 | |
| Allen Annis | Aileron Therapeutics | 51 | |
| Leslie Robbins | CytomX Therapeutics | N/A | |
| Pratik Shah | Design Therapeutics | 54 | |
| James Windsor | Aileron Therapeutics | 58 | |
| Brian Windsor | Aileron Therapeutics | 57 | |
Management Performance
| Return On Equity | -2.81 | |||
| Return On Asset | -0.42 |
Aeglea Bio Therapeutics Leadership Team
Elected by the shareholders, the Aeglea Bio's board of directors comprises two types of representatives: Aeglea Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aeglea. The board's role is to monitor Aeglea Bio's management team and ensure that shareholders' interests are well served. Aeglea Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aeglea Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James JD, Pres CEO | ||
| Jonathan MBA, CFO Officer | ||
| Michael MBA, Chief Officer | ||
| Josie Gayton, Operations Strategy | ||
| Cortney MBA, VP Operations | ||
| Leslie Sloan, Chief Officer | ||
| Kelly Boothe, Sr Relations | ||
| Jeffrey Goldberg, CEO Pres | ||
| Joey Perrone, Director- Finance, IR Contact Officer | ||
| Scott Rowlinson, Vice President - Research | ||
| MBA MD, Chief Officer |
Aeglea Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aeglea Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.81 | |||
| Return On Asset | -0.42 | |||
| Operating Margin | (94.85) % | |||
| Current Valuation | 228.21 M | |||
| Shares Outstanding | 4.05 M | |||
| Shares Owned By Insiders | 2.40 % | |||
| Shares Owned By Institutions | 97.60 % | |||
| Number Of Shares Shorted | 128.62 K | |||
| Price To Earning | (2.41) X | |||
| Price To Book | 0.35 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Aeglea Stock
If you are still planning to invest in Aeglea Bio Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aeglea Bio's history and understand the potential risks before investing.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |